Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Travere ...

Analysts anticipate Travere Therapeutics to report an earnings per share (EPS) of $0.24. The market awaits Travere ...

The drug developer posted revenue of $129.7 million in the period, which did not meet Street forecasts. Six analysts surveyed by Zacks expected $142.5 million. For the year, the company reported a ...

FILSPARI generated $103.3 million in U.S. net product sales for Q4 and $322 million for the full year. Thiola and Thiola EC contributed $23.3 million in U.S. net product sales during Q4 and $88.5 ...

Learn more about whether IDEAYA Biosciences, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...

Travere Therapeutics (NASDAQ: TVTX) reported its Q4 earnings results on Thursday, February 19, 2026 at 04:01 PM. Here's what investors need to know about the announcement. Travere Therapeutics beat ...

For the quarter ended December 2025, Travere Therapeutics (TVTX) reported revenue of $129.69 million, up 73.4% over the same period last year. EPS came in at $0.03, compared to -$0.73 in the year-ago ...

If you are wondering whether Travere Therapeutics at around US$27.82 still offers value, you are not alone, many investors are asking the same question as the stock has been on the radar of biotech ...

Travere Therapeutics Inc reports fourth-quarter earnings Thursday after market close, with investors focused on the rare disease specialist’s commercial momentum following a regulatory setback that ...

Travere Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Genomics, Inc. , a leader in single cell and spatial biology, announced today that members of its management team will ...